Profile banner
Anne-Sophie Saint-Martin

Anne-Sophie Saint-Martin

Early-stage VC Partner focused on HealthTech, AI, and neuroscience

anne-saint
Paris, France
Joined April 2026

Network

20.3K connections
🌱
Early-Stage VC Investors
🇫🇷
Bpifrance Network
⚕️
HealthTech Founders
🤝
Newfund VC Team
🤖
DeepTech AI Innovators
⚙️
VC Operating Support
🌍
Impact

Summary

Anne-Sophie Saint-Martin is a highly experienced early-stage venture capital Partner at Newfund, specializing in HealthTech. She is particularly focused on AI and neuroscience within this sector, having co-founded Heka, a dedicated braintech fund. Her investment areas include AI-enabled diagnostics, digital therapeutics, predictive analytics, personalized care, and accelerating clinical trials, with a keen interest in impact investing for conditions like mental and neurological diseases. newfundcap+3
With a background as an engineer and R&D scientist, Anne-Sophie brings a technical and scientific foundation to her investment strategies. Her early career involved biotech R&D at Cylene Pharmaceuticals and innovation project management at Solvay, followed by a role as an Innovation Business Manager at Bpifrance where she financed numerous startups. This blend of scientific expertise, corporate finance, and business strategy informs her approach to identifying and supporting disruptive technologies in healthcare. theorg+2
Anne-Sophie is a prolific writer and thought leader, regularly contributing to the Newfund blog and participating in interviews to share her insights on braintech, sleeptech, psychedelics, and empowering women entrepreneurs. Her publications demonstrate a deep engagement with the evolving landscape of health technology and a commitment to fostering innovation and supporting founders. newfundcap+2

Work

Education

Writing

Investing for impact in braintech, interview w. Anne-Sophie Saint-Martin (Newfund)

July 1, 2024

An interview detailing her perspective on investing in braintech, focusing on its impact areas like AI-enabled diagnostics, digital therapeutics, and personalized care.

Favicon imageeu.vc

Skills enhancement startups: an investor point of view

December 1, 2023

An article discussing skills enhancement in the context of BrainTech, as part of a series on the BrainTech market from an investor's perspective.

Favicon imageblog.newfundcap.com

The SleepTech Industry: an Investor Perspective

October 1, 2023

This article explores the SleepTech industry, defining it and discussing its technology sector, as part of a series on the BrainTech market.

Favicon imageblog.newfundcap.com

Empowering women entrepreneurs

June 1, 2023

An analysis of gender diversity in Newfund's dealflow and a 2023 action plan to empower women entrepreneurs, showing commitment to diversity and inclusion.

Favicon imageblog.newfundcap.com

Psychedelics: an investor perspective

March 1, 2023

An article that addresses the psychedelic market from an investor's perspective, as part of a series on the BrainTech market.

Favicon imageblog.newfundcap.com

Brain Computer Interface : an investor perspective

March 1, 2023

This article discusses Brain Computer Interface (BCI) from an investor's perspective, highlighting it as an emerging sector of innovation within BrainTech.

Favicon imageblog.newfundcap.com

Brain & nutrition: the new challenges of innovation

June 1, 2022

Explores the link between gut microbiota, mental health, and nutrition, and related therapeutic innovations developed by startups.

Favicon imageblog.newfundcap.com

What can a VC do for your brain?

October 1, 2021

This article studies 160 European startups active in mental health, divided into four segments: personal solutions, professional diagnostics and treatments, business solutions, and practitioner tools.

Favicon imageblog.newfundcap.com

Notes

FVFrançois Véronsaid
ASAnne-Sophie Saint-Martin
is among the most effective senior leaders they know when it comes to driving AI missions forward.

Nov 10, 2025